Wellgistics Health Converts $8.1M Debt to Equity
Wellgistics Health (NASDAQ:WGRX), a leader in pharmaceutical distribution and AI-powered prescription services, has announced the conversion of $8.1 million in debt to equity. The transaction, approved by the Board of Directors and led by CEO Brian Norton along with former Wellgistics LLC minority partners, aims to strengthen the company's balance sheet by reducing short-term debt.
The strategic move is expected to improve cash flow, enhance access to capital, enable better pharmaceutical product acquisition, expand the company's independent pharmacy network, and strengthen its proprietary technology platform. CFO Mark DiSiena expressed confidence that this conversion will help accelerate the company's business plan and drive long-term shareholder value.
Wellgistics Health (NASDAQ:WGRX), leader nella distribuzione farmaceutica e nei servizi di prescrizione basati su intelligenza artificiale, ha annunciato la conversione di 8,1 milioni di dollari di debito in capitale sociale. L'operazione, approvata dal Consiglio di Amministrazione e guidata dall'amministratore delegato Brian Norton insieme agli ex soci di minoranza di Wellgistics LLC, mira a rafforzare il bilancio aziendale riducendo il debito a breve termine.
Questa mossa strategica dovrebbe migliorare il flusso di cassa, facilitare l'accesso al capitale, consentire un'acquisizione più efficiente di prodotti farmaceutici, ampliare la rete di farmacie indipendenti dell'azienda e potenziare la piattaforma tecnologica proprietaria. Il CFO Mark DiSiena ha espresso fiducia che questa conversione accelererà il piano aziendale e genererà valore duraturo per gli azionisti.
Wellgistics Health (NASDAQ:WGRX), líder en distribución farmacéutica y servicios de prescripción impulsados por inteligencia artificial, ha anunciado la conversión de 8,1 millones de dólares en deuda a capital. La transacción, aprobada por la Junta Directiva y liderada por el CEO Brian Norton junto con antiguos socios minoritarios de Wellgistics LLC, tiene como objetivo fortalecer el balance de la empresa reduciendo la deuda a corto plazo.
Esta medida estratégica se espera que mejore el flujo de caja, facilite el acceso a capital, permita una mejor adquisición de productos farmacéuticos, amplíe la red de farmacias independientes de la compañía y fortalezca su plataforma tecnológica propietaria. El CFO Mark DiSiena expresó confianza en que esta conversión ayudará a acelerar el plan de negocios y a generar valor a largo plazo para los accionistas.
Wellgistics Health (NASDAQ:WGRX)는 제약 유통과 AI 기반 처방 서비스 분야의 선두주자로서, 810만 달러의 부채를 자본으로 전환한다고 발표했습니다. 이 거래는 이사회 승인 하에 CEO 브라이언 노턴과 전 Wellgistics LLC 소수 파트너들이 주도했으며, 단기 부채를 줄여 회사의 재무구조를 강화하는 것을 목표로 합니다.
이 전략적 조치는 현금 흐름 개선, 자본 접근성 향상, 제약 제품 구매 능력 강화, 독립 약국 네트워크 확대, 독자적인 기술 플랫폼 강화에 기여할 것으로 기대됩니다. CFO 마크 디시에나는 이번 전환이 회사의 사업 계획 가속화와 장기 주주 가치 창출에 도움이 될 것이라 확신했습니다.
Wellgistics Health (NASDAQ:WGRX), un leader dans la distribution pharmaceutique et les services de prescription basés sur l'intelligence artificielle, a annoncé la conversion de 8,1 millions de dollars de dette en capitaux propres. Cette opération, approuvée par le conseil d'administration et menée par le PDG Brian Norton avec d'anciens partenaires minoritaires de Wellgistics LLC, vise à renforcer le bilan de l'entreprise en réduisant la dette à court terme.
Cette démarche stratégique devrait améliorer la trésorerie, faciliter l'accès au capital, permettre une meilleure acquisition de produits pharmaceutiques, étendre le réseau de pharmacies indépendantes de la société et renforcer sa plateforme technologique propriétaire. Le directeur financier Mark DiSiena a exprimé sa confiance que cette conversion accélérera le plan d'affaires de l'entreprise et créera une valeur durable pour les actionnaires.
Wellgistics Health (NASDAQ:WGRX), ein führendes Unternehmen im Bereich Pharmavertrieb und KI-gestützter Verschreibungsdienste, hat die Umwandlung von 8,1 Millionen US-Dollar Schulden in Eigenkapital bekanntgegeben. Die Transaktion, die vom Vorstand genehmigt wurde und unter der Leitung von CEO Brian Norton sowie ehemaligen Minderheitsgesellschaftern von Wellgistics LLC steht, zielt darauf ab, die Bilanz des Unternehmens durch Reduzierung der kurzfristigen Schulden zu stärken.
Dieser strategische Schritt soll den Cashflow verbessern, den Zugang zu Kapital erleichtern, den Erwerb von pharmazeutischen Produkten optimieren, das unabhängige Apothekennetzwerk erweitern und die firmeneigene Technologieplattform stärken. CFO Mark DiSiena zeigte sich zuversichtlich, dass diese Umwandlung dazu beitragen wird, den Geschäftsplan zu beschleunigen und langfristigen Aktionärswert zu schaffen.
- Conversion of $8.1M debt to equity strengthens balance sheet
- Reduction in short-term debt obligations improves financial flexibility
- Enhanced ability to acquire pharmaceutical products at competitive prices
- Expected improvement in cash flow and capital access terms
- Potential expansion of independent pharmacy network
- Potential dilution of existing shareholders due to debt-to-equity conversion
TAMPA, FLORIDA / ACCESS Newswire / July 25, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that its Board of Directors has approved an
Led by CEO Brian Norton and former minority partners of Wellgistics, LLC, which was acquired by Wellgistics Health in 2024, the transaction strengthens the Company's balance sheet by materially reducing the Company's short-term debt.
The transaction is also expected to:
Accelerate the Company's cash flow by unlocking more favorable terms and capital access;
Improve Wellgistics Health's ability to acquire high-demand pharmaceutical products at competitive prices;
Expand the Company's national footprint by growing its network of independent pharmacies; and
Strengthen the Company's proprietary technology platform, including AI-powered hub services and digital prescription routing
"This conversion will make a significant contribution in enabling us to accelerate our business plan and accomplish the goals we believe will help transform the prescription drug marketplace and drive long-term value for our shareholders," said Wellgistics Health CFO Mark DiSiena.
"We look forward to sharing additional positive developments in the near future."
About Wellgistics Health
Wellgistics Health (NASDAQ: WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ independent pharmacies and 200+ U.S. manufacturers, offering wholesale distribution, digital script routing, and AI-driven hub services like eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health delivers seamless, compliant, end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov.
For more information, please contact:
Media Contact: media@wellgisticshealth.com
Investor Relations: investors@wellgisticshealth.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the size of Wellgistics Health's (WGRX) debt-to-equity conversion?
Who led the WGRX debt conversion transaction?
What are the expected benefits of Wellgistics Health's debt conversion?
How will the debt conversion affect Wellgistics Health's balance sheet?
When did Wellgistics Health acquire Wellgistics LLC?
